Figure 5.

In vivo downregulation of PD-L1 in MDA-MB-231 tumors treated with PD-L1 siRNA dextran. (A) Correlation between the levels of PD-L1 mRNA, represented by PD-L1 fold change relative to control tumors, and the tumor/muscle fluorescence ratio in tumors treated with PD-L1 siRNA dextran NPs. (B) Relative fold change of PD-L1 mRNA expression in MDA-MB-231 tumors treated with the PD-L1 siRNA dextran NPs. Mice were injected with PBS, or PD-L1 siRNA dextran NPs through the tail vein. Animals were divided, according to the tumor to muscle fluorescence ratio measured in vivo, into the highest (triangles) and lowest (squares) 50% values. Fold changes were normalized to tumors treated with PBS. Lines represent Mean ± Standard Error of the Mean. **p < 0.01 compared to control tumors or low tumor to muscle fluorescence ratio tumors.